Physician profile
Alice Sterling
NPI 1588655542
$5,567.42
in general payments reported to CMS, 2019-2025
21 companies · $986 in 2025
The $986 reported for 2025 was more than what 91% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,013 · 2020: $180 · 2021: $1,342 · 2022: $653 · 2023: $575 · 2024: $816 · 2025: $986.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,217 · Entertainment: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,217.21 |
| Entertainment | $161.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,720.55 | 2019-2025 | Tryptyr, Rocklatan, Rhopressa |
| Bausch & Lomb Americas INC. | $867.79 | 2022-2025 | Infuse, Xiidra, Miebo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $463.89 | 2019-2020 | |
| Oyster Point Pharma, INC. | $385.32 | 2022-2024 | Tyrvaya |
| Harrow Eye, LLC | $236.48 | 2025 | Vevye |
| Allergan, INC. | $230.02 | 2019-2022 | |
| Johnson & Johnson Vision Care, INC. | $223.21 | 2019-2025 | |
| Optos, INC. | $182.33 | 2021-2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Glaukos Corporation | $151.60 | 2024 | Ce-Marked Kxla System |
| Apellis Pharmaceuticals, INC. | $121.82 | 2024 | Syfovre |
| Tarsus Pharmaceuticals, INC. | $121.82 | 2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $120.81 | 2021 | |
| Maculogix, INC. | $115.96 | 2020 | |
| Rxsight INC | $113.27 | 2022 | |
| Sun Pharmaceutical Industries INC. | $111.14 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optovue, INC. | $108.46 | 2019-2021 | |
| Shire North American Group INC | $83.30 | 2019 | |
| Abbvie INC. | $78.00 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $54.67 | 2019-2021 | |
| Horizon Therapeutics Plc | $53.25 | 2023 | Tepezza |
| Coopervision INC. | $23.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alice Sterling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.